2. Academic Validation
  3. Selective Sirt2 inhibition by ligand-induced rearrangement of the active site

Selective Sirt2 inhibition by ligand-induced rearrangement of the active site

  • Nat Commun. 2015 Feb 12;6:6263. doi: 10.1038/ncomms7263.
Tobias Rumpf 1,  Matthias Schiedel 1,  Berin Karaman 2,  Claudia Roessler 3,  Brian J North 4,  Attila Lehotzky 5,  Judit Oláh 5,  Kathrin I Ladwein 1,  Karin Schmidtkunz 1,  Markus Gajer 1,  Martin Pannek 6,  Clemens Steegborn 6,  David A Sinclair 4,  Stefan Gerhardt 7,  Judit Ovádi 5,  Mike Schutkowski 3,  Wolfgang Sippl 2,  Oliver Einsle 7,  Manfred Jung 1
Affiliations

Affiliations

  • 1 Institute of Pharmaceutical Sciences, Albert-Ludwigs-University Freiburg, Albertstraße 25, 79104 Freiburg im Breisgau, Germany.
  • 2 Institute for Pharmacy, Martin-Luther-University Halle-Wittenberg, Wolfgang-Langenbeck-Straße 4, 06120 Halle (Saale), Germany.
  • 3 Institute for Biochemistry and Biotechnology, Martin-Luther-University Halle-Wittenberg, Kurt-Mothes-Straße 3, 06120 Halle (Saale) Germany.
  • 4 Department of Genetics, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA.
  • 5 Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar Tudósok körútja 2, H-1117 Budapest, Hungary.
  • 6 Department of Biochemistry, University of Bayreuth, Universitätsstraße 30, 95445 Bayreuth, Germany.
  • 7 Institute for Biochemistry and BIOSS Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg im Breisgau, Albertstraße 21, 79104 Freiburg im Breisgau, Germany.
PMID: 25672491 DOI: 10.1038/ncomms7263
Abstract

Sirtuins are a highly conserved class of NAD(+)-dependent lysine deacylases. The human isotype SIRT2 has been implicated in the pathogenesis of Cancer, inflammation and neurodegeneration, which makes the modulation of SIRT2 activity a promising strategy for pharmaceutical intervention. A rational basis for the development of optimized SIRT2 inhibitors is lacking so far. Here we present high-resolution structures of human SIRT2 in complex with highly selective drug-like inhibitors that show a unique inhibitory mechanism. Potency and the unprecedented SIRT2 selectivity are based on a ligand-induced structural rearrangement of the active site unveiling a yet-unexploited binding pocket. Application of the most potent Sirtuin-rearranging ligand, termed SirReal2, leads to tubulin hyperacetylation in HeLa cells and induces destabilization of the checkpoint protein BubR1, consistent with SIRT2 inhibition in vivo. Our structural insights into this unique mechanism of selective Sirtuin inhibition provide the basis for further inhibitor development and selective tools for Sirtuin biology.

Figures